OncoGenex cancer drug reduces risk of death in metastatic bladder cancer
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 9:05AM CST
OGXI: 2.10 (-0.04)
OncoGenex Announces Results from the Phase 2 Borealis-1(TM) Trial of Apatorsen in the Treatment of Metastatic Bladder Cancer
PR Newswire - Fri Dec 19, 7:00AM CST
Exploratory Analysis Shows Addition of 600mg Apatorsen to Standard of Care Chemotherapy Resulted in 50 Percent Reduction in Risk of Death in Patients with Lower Performance Status
OGXI: 2.10 (-0.04)
OncoGenex's Pancreatic Cancer Study Fully Enrolled - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 2:10PM CST
OncoGenex Pharmaceuticals, Inc. (OGXI) has completed enrolling patients in its phase II Rainier study on apatorsen for previously untreated metastatic pancreatic cancer.
LCI: 42.29 (+1.79), OGXI: 2.10 (-0.04), PFE: 31.42 (-0.03), NVS: 93.91 (+0.66)
OncoGenex Announces Completion of Patient Enrollment in the Rainier(TM) Clinical Trial Evaluating Apatorsen in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer
CNW Group - Tue Dec 16, 5:30AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that patient enrollment has been completed in the RainierTM clinical trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen in combination with ABRAXANE(®) (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Rainier is sponsored and led by the Sarah Cannon Research Institute (SCRI) and is being conducted at 11 sites in the United States.
OGXI: 2.10 (-0.04)
5 Stocks Poised for Breakouts: Trulia and More
at The Street - Fri Dec 12, 11:36AM CST
These are the stocks that often go on to make monster moves to the upside.
TILE: 16.39 (-0.02), OGXI: 2.10 (-0.04), MOBL: 9.75 (+0.26), TRLA: 45.55 (+0.01), MCHX: 5.20 (-0.05)
OncoGenex: Deep Pipeline For Microcap Offers Significant Upside
Daniel Ward - at Seeking Alpha - Wed Dec 10, 9:11AM CST
OGXI: 2.10 (-0.04)
OncoGenex Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference
CNW Group - Mon Nov 17, 5:30AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 10:55 a.m. ET at the New York Palace Hotel in New York City. The presentation will include an overview of apatorsen Phase 2 development plans, as well as additional data from custirsen Phase 3 SYNERGY exploratory analyses.
OGXI: 2.10 (-0.04)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 340.89 (+5.13), ALNY: 93.52 (+0.97), ISIS: 59.49 (+1.88), OGXI: 2.10 (-0.04), TEVA: 57.09 (+0.33), RGLS: 14.78 (+0.24), GSK: 42.85 (+0.11), SNY: 46.35 (+0.50)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 6.49 (+0.29), PCYC: 121.84 (+1.15), CLDX: 17.08 (-0.18), INCY: 71.57 (+1.99), BIND: 5.73 (+0.06), CELG: 109.60 (+3.48), OMER: 22.09 (+0.48), VSTM: 8.30 (+0.19), GILD: 91.29 (+1.84), OGXI: 2.10 (-0.04), ANTH: 1.48 (unch), NVAX: 5.81 (+0.18)
OncoGenex Pharmaceuticals' (OGXI) CEO Scott Cormack on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 3:04AM CST
OGXI: 2.10 (-0.04)
More on OncoGenex Pharmaceuticals Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 1:32PM CDT
OGXI: 2.10 (-0.04)
OncoGenex Pharmaceuticals beats by $0.14, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:34PM CDT
OGXI: 2.10 (-0.04)
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014
CNW Group - Thu Oct 30, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced third quarter 2014 financial results.
OGXI: 2.10 (-0.04), TEVA: 57.09 (+0.33)
Some Of Soros' Stocks Surged Today, While Others Soured
at The Street - Wed Oct 29, 3:31PM CDT
OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), MCG Capital Corp (NASDAQ:MCGC) and Doral Financial Corp. (NYSE
OGXI: 2.10 (-0.04), MCGC: 3.95 (+0.02), INVN: 16.22 (+0.27), DRL: 3.38 (-0.02), ARCP: 8.33 (unch)
OncoGenex reports on October 30
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 9:27AM CDT
OGXI: 2.10 (-0.04)
OncoGenex to Report Financial Results for Third Quarter 2014 on October 30, 2014
PR Newswire - Thu Oct 16, 5:30AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter 2014 financial results will be released on Thursday, October 30, 2014, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the company's financial results, development programs and a general business update.
OGXI: 2.10 (-0.04)